Compounds > duloxetine
Page last updated: 2024-08-24

duloxetine and atomoxetine

duloxetine has been researched along with atomoxetine in 9 studies

Research

Studies (9)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's6 (66.67)29.6817
2010's3 (33.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Beedle, EE; Bymaster, FP; Findlay, J; Gallagher, PT; Krushinski, JH; Mitchell, S; Robertson, DW; Thompson, DC; Wallace, L; Wong, DT1
Chen, C; Dyck, B; Fleck, BA; Foster, AC; Grey, J; Jovic, F; Mesleh, M; Phan, K; Tamiya, J; Vickers, T; Zhang, M1
Alfinito, P; Bray, J; Cohn, ST; Deecher, DC; Fensome, A; Johnston, G; Koury, E; Mahaney, PE; Marella, MA; McComas, CC; Nogle, L; Trybulski, EJ; Vu, AT; Ye, F; Zhang, P1
Bradbury, MJ; Chen, C; Dyck, B; Fleck, BA; Foster, AC; Grey, J; Johns, M; Jovic, F; Li, B; Madan, A; O'Brien, J; Pick, RR; Saunders, J; Tamiya, J; Tran, JA; Vickers, T; Wen, J; Zhang, M1
Childers, SR; Davies, HM; Manning, JR; Sexton, T1
Bray, JA; Cohn, ST; Deecher, DC; Dooley, R; Goljer, I; Johnston, GH; Leiter, J; Mahaney, PE; Moore, WJ; Terefenko, EA; Trybulski, EJ; Vu, AT; Zhang, P1
Alelyunas, YW; Bui, K; Empfield, JR; McCarthy, D; Pelosi-Kilby, L; Shen, C; Spreen, RC1
Dalvie, D; Loi, CM; Smith, DA1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1

Reviews

1 review(s) available for duloxetine and atomoxetine

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Other Studies

8 other study(ies) available for duloxetine and atomoxetine

ArticleYear
Duloxetine (Cymbalta), a dual inhibitor of serotonin and norepinephrine reuptake.
    Bioorganic & medicinal chemistry letters, 2003, Dec-15, Volume: 13, Issue:24

    Topics: Antidepressive Agents; Binding Sites; Clinical Trials as Topic; Depressive Disorder; Duloxetine Hydrochloride; Humans; Kinetics; Norepinephrine; Selective Serotonin Reuptake Inhibitors; Structure-Activity Relationship; Thiophenes

2003
Studies on the SAR and pharmacophore of milnacipran derivatives as monoamine transporter inhibitors.
    Bioorganic & medicinal chemistry letters, 2008, Feb-15, Volume: 18, Issue:4

    Topics: Acetamides; Alkylation; Amides; Cyclopropanes; Indoles; Milnacipran; Models, Molecular; Molecular Conformation; Nuclear Magnetic Resonance, Biomolecular; Stereoisomerism; Structure-Activity Relationship; Vesicular Monoamine Transport Proteins

2008
Synthesis and activity of 1-(3-amino-1-phenylpropyl)indolin-2-ones: a new class of selective norepinephrine reuptake inhibitors.
    Bioorganic & medicinal chemistry letters, 2008, Sep-15, Volume: 18, Issue:18

    Topics: Humans; Indoles; Molecular Structure; Neurotransmitter Uptake Inhibitors; Norepinephrine; Stereoisomerism; Structure-Activity Relationship

2008
Characterization of thien-2-yl 1S,2R-milnacipran analogues as potent norepinephrine/serotonin transporter inhibitors for the treatment of neuropathic pain.
    Journal of medicinal chemistry, 2008, Nov-27, Volume: 51, Issue:22

    Topics: Administration, Oral; Animals; Biological Availability; Caco-2 Cells; Crystallography, X-Ray; Cyclopropanes; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Design; Humans; Male; Microsomes, Liver; Milnacipran; Models, Molecular; Molecular Structure; Molecular Weight; Neuralgia; Norepinephrine Plasma Membrane Transport Proteins; Pain Measurement; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors; Serotonin Plasma Membrane Transport Proteins; Spinal Nerves; Stereoisomerism; Structure-Activity Relationship

2008
1-Naphthyl and 4-indolyl arylalkylamines as selective monoamine reuptake inhibitors.
    Bioorganic & medicinal chemistry letters, 2009, Jan-01, Volume: 19, Issue:1

    Topics: Amines; Animals; Antidepressive Agents, Second-Generation; Biogenic Monoamines; Dopamine Antagonists; Dopamine Uptake Inhibitors; Drug Design; Humans; Neurotransmitter Uptake Inhibitors; Protein Binding; Selective Serotonin Reuptake Inhibitors; Serotonin Antagonists; Stereoisomerism

2009
3-(Arylamino)-3-phenylpropan-2-olamines as a new series of dual norepinephrine and serotonin reuptake inhibitors.
    Bioorganic & medicinal chemistry letters, 2009, May-01, Volume: 19, Issue:9

    Topics: Adrenergic Uptake Inhibitors; Animals; Chemistry, Pharmaceutical; Dogs; Dopamine Plasma Membrane Transport Proteins; Drug Design; Humans; Inhibitory Concentration 50; Ligands; Models, Chemical; Norepinephrine; Propanolamines; Selective Serotonin Reuptake Inhibitors; Structure-Activity Relationship

2009
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
    Bioorganic & medicinal chemistry letters, 2010, Dec-15, Volume: 20, Issue:24

    Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility

2010
Which metabolites circulate?
    Drug metabolism and disposition: the biological fate of chemicals, 2013, Volume: 41, Issue:5

    Topics: Humans; Metabolic Clearance Rate; Pharmaceutical Preparations

2013